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ARTICLE
Somatic SF3B1 hotspot mutation in prolactinomas
Chuzhong Li 1,2,3,4,13, Weiyan Xie 1,13, Jared S. Rosenblum 5, Jianyu Zhou6, Jing Guo1,2, Yazhou Miao1,2,
Yutao Shen1,2, Hongyun Wang1, Lei Gong1, Mingxuan Li1,2, Sida Zhao1,2, Sen Cheng1,2, Haibo Zhu1,2,
Tao Jiang 6,7, Shiying Ling8, Fei Wang8, Hongwei Zhang9, Mingshan Zhang9, Yanming Qu9, Qi Zhang5,
Guilin Li10, Junmei Wang10, Jun Ma11, Zhengping Zhuang 5,12✉ & Yazhuo Zhang 1,2,3,4✉
The genetic basis and corresponding clinical relevance of prolactinomas remain poorly
understood. Here, we perform whole genome sequencing (WGS) on 21 patients with pro-
lactinomas to detect somatic mutations and then validate the mutations with digital poly-
merase chain reaction (PCR) analysis of tissue samples from 227 prolactinomas. We identify
the same hotspot somatic mutation in splicing factor 3 subunit B1 (SF3B1R625H) in 19.8%
of prolactinomas. These patients with mutant prolactinomas display higher prolactin (PRL)
levels (p= 0.02) and shorter progression-free survival (PFS) (p= 0.02) compared to
patients without the mutation. Moreover, we identify that the SF3B1R625H mutation causes
aberrant splicing of estrogen related receptor gamma (ESRRG), which results in stronger
binding of pituitary-specific positive transcription factor 1 (Pit-1), leading to excessive PRL
secretion. Thus our study validates an important mutation and elucidates a potential
mechanism underlying the pathogenesis of prolactinomas that may lead to the development
of targeted therapeutics.
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The prevalence of pituitary adenomas (PAs) is ~0.1% inadults and nearly half of them are prolactinomas1, whichare typically characterized by increased PRL secretion with
related endocrinological symptoms. Mass effects including
headaches and visual field defects may occur with parasellar
extension of macroadenomas. A subset of prolactinomas may
become aggressive and resist therapies1, but the mechanism of
aggressive biological behavior has not been fully determined.
The genetic causes of PAs remain unclear but studies have
reported that they have the low mutational burden, reflected by
their benign nature2. Only several driver mutations have been
identified to date in PAs, including guanine nucleotide-binding
protein subunit alpha S (GNAS) in somatotroph adenomas3 and
ubiquitin-specific protease 8 (USP8), USP48 and B-Raf proto-
oncogene (BRAF) in corticotroph adenomas4,5. In prolactinomas,
no high-frequency genetic alterations have been reported, which
greatly hindered the understanding of tumor pathogenesis and
the development of therapeutic strategies.
Herein, we conduct a genomic analysis of resected prolacti-
nomas using whole-genome sequencing (WGS) and identify a
hotspot mutation in SF3B1, a component of the U2 small nuclear
ribonucleoproteins (snRNP) complex, which has been implicated
in other cancer types6–8. We then validate the mutation in an
additional set of prolactinomas. We demonstrate herein that the
identified mutation of SF3B1 results in aberrant splicing of
ESRRG—a member of the estrogen receptor-related receptor
(ESRR) family—leading to abnormal PRL secretion and tumor-
igenesis in prolactinomas. This finding may represent a distinct
genotype of prolactinomas with unique clinical implications and
contributes to the understanding of the molecular mechanism of
prolactinomas.
Results
Identification of hotspot SF3B1R625H mutation in prolactino-
mas. We performed WGS on an initial set of 21 prolactinomas to
detect somatic mutations. Ninety somatic mutations in 88 genes
were identified using WGS (median, 4; range, 0–21) in the initial
patient set (n= 21) (Fig. 1a; Supplementary Table 1, 2). Only
SF3B1 was found to be mutated in more than one sample (n= 2;
c.G1874A; p.R625H), which was confirmed by Sanger sequencing
(Supplementary Fig. 1). Examination of the SF3B1 coding
sequence showed no additional mutations in the gene. The
mutation in SF3B1 was validated with digital PCR analysis of 227
prolactinomas including the 21 cases.
Microfluidic-chamber-based digital PCR analysis performed on
SF3B1R625H in the prolactinoma tumor samples obtained from an
additional 178 prolactinomas (validation set 1) found 38
SF3B1R625H mutations (Fig. 1b). Of the 38 samples, 11 available
paired blood samples showed no mutation. Including the initial
patient set (n= 21), 20.1% (40/199) had the mutation. The results
in the main study group were further validated in an independent
medical center group of prolactinomas (validation set 2, n= 28)
(Fig. 1c), in which SF3B1R625H was found in five samples (17.9%)
by PCR analysis of c.G1874A (p.R625H) (Supplementary Table 3).
Thus, the total number of SF3B1R625H mutant prolactinomas
identified was 45/227, 19.8%. Overview on the patients included
in this study and summary of SF3B1 mutational status of these
patients are shown in Supplementary Table 1.
To study the prevalence of SF3B1R625H mutation in other types
of PAs, we screened an additional 154 PAs. There were no
SF3B1R625H mutation in such pathological types of PAs (n=
120), including 18 thyrotroph adenomas, 33 somatotroph, 30
gonadotroph, 24 corticotroph, and 15 null cell adenomas. In the
remaining 34 tumors, 1 of 16 plurihormonal (6.3%) and 1 of 18
mammosomatotroph/mixed adenomas (5.6%) showed the
mutation. These two tumors with the mutation both have a
positive immunostaining for PRL. Thus, the SF3B1R625H muta-
tion was only detected in PRL immune-positive PAs.
SF3B1 is the most frequently mutated spliceosome gene, which
has an oncogenic role by alternative splicing of pre-mRNAs,
resulting in complexity and flexibility in gene expression9,10.
Phylogenetic analysis of SF3B1R625H locus across species
indicated a high conservation level (Supplementary Fig. 2),
suggesting an essential role in gene expression and post-
transcriptional regulation. Mutations of SF3B1 in other diseases
are typically located in HEAT (Huntingtin, elongation factor 3,
protein phosphatase 2 A and the yeast PI3-kinase TOR1) repeat
domains6,8,11. The R625 residue found herein mutated is located
in the fourth HEAT repeat (Supplementary Fig. 2). R625
mutations in SF3B1 have been described in uveal melanoma,
vulvovaginal mucosal melanoma, and other cancers8,12,13. The
location of the mutation we identified in these prolactinomas,
consistent with mutations in other cancers, suggests the mutation
significantly alters function based on its location.
Impact of SF3B1R625H on prolactinoma function. To assess the
role of SF3B1R625H in prolactinomas, we established primary cell
cultures of surgically resected human prolactinomas. We assessed
PRL secretions in culture media from mutant and wild-type
culture tumor cells. The PRL level in the cell supernatant of the
mutant group was higher than the wild type (Fig. 2a). Involve-
ment of endogenous SF3B1 was tested by using short interfering
RNA (siRNA); knockdown efficiency was verified by quantitative
Real-time PCR (qRT-PCR) and western blot (Fig. 2b, Supple-
mentary Fig. 3). SF3B1 siRNA resulted in decreased PRL secre-
tion in primary culture prolactinoma cells (Fig. 2c). Further, we
infected the primary culture prolactinoma cells with adenovirus
with SF3B1WT and SF3B1R625H. SF3B1 mutation resulted in a
significant augment of PRL secretion (Fig. 2d). These results
demonstrated increasing PRL secretion with this mutation in
human prolactinoma cells.
We then investigated the role and function of SF3B1R625H
mutation in the development of prolactinomas by performing
colony formation, cell counting kit-8 (CCK-8) and flow
cytometry on rat GH3/MMQ pituitary cells with ectopic gene
expression at the indicated multiplicity of infection (MOI)
(Supplementary Fig. 4) and stable cell line, respectively. Over-
expression of SF3B1R625H by adenovirus improved the focus
formation of GH3 and MMQ cells (Fig. 2e, h and Supplementary
Fig. 5a). After infection of adenovirus expressing SF3B1WT and
SF3B1R625H, respectively, CCK-8 assay was executed to detect the
effect of SF3B1R625H on the proliferation. These results showed
SF3B1R625H increased the growth of GH3 and MMQ cells
compared with control (Fig. 2f, i). To determine the influence of
SF3B1R625H on the apoptosis of GH3 and MMQ cells, we
conducted Annexin V/propidium iodide (PI) staining and flow
cytometry. The results revealed that the percentages of early and
late apoptosis of GH3 and MMQ cells were decreased by
SF3B1R625H compared with control (Fig. 2g, j and Supplementary
Fig. 5c). Then, we confirmed these findings by a stable GH3 cell
line established with the infection of a lentivirus containing
SF3B1WT and SF3B1R625H (Fig. 2k, l, m, and Supplementary
Fig. 5b, c). Considered together, these data indicate that
SF3B1R625H enhances proliferation and suppress apoptosis of
GH3 and MMQ cells.
SF3B1R625H induces aberrant splicing of ESRRG. RNA-seq and
rMATS analysis found 112 significantly different splicing events
(98 genes) between prolactinomas with or without SF3B1 muta-
tion (Supplementary Table 4). This included 35 alternative 3′
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splice sites (A3SS), 2 alternative 5′ splice sites (A5SS), 22 mutually
exclusive exons, 36 skipped exons, and 17 retained introns. A
significant overrepresentation of regulated A3SS was found in the
comparison of SF3B1R625H with wild-type tumors (Supplementary
Fig. 6a). These genes all showed upstream cryptic 3′ splice sites
with the cryptic AG site located between 16 and 25 nucleotides
upstream of the canonical site (Supplementary Fig. 6b). These data
reflect the importance of structural similarity in recognizing the
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Fig. 1 Recurrent SF3B1 Mutations in prolactinomas. a The mutational landscape of 21 prolactinomas. Samples are displayed in columns from left to right.
Each row represents a gene. The rates of synonymous and non-synonymous mutations are expressed in the number of mutations per megabase (Mb) and
are displayed in the top panel. The somatic mutation frequencies for each candidate gene are plotted on the right panel. Mutations that were not validated
through Sanger sequencing and time of flight mass spectrometer (TOF), because of an unsuccessful amplification or lack of remaining tissues, are
represented by a white slash. Mutation types are color-coded as indicated above the image. All candidate genes are considered capable of expression with
FPKM of over 1 in >20% of all RNA samples. b, c Detection of SF3B1R625H mutations in the prolactinoma tumor samples. The top chart shows the fractional
abundance of variants on microfluidic-chamber-based digital PCR analysis in prolactinoma tissue samples. The samples are shown according to the order
of highest to lowest frequency, b the section 1 included 172 patients from Beijing Tiantan Hospital affiliated to Capital Medical University, c the section 2
included 27 patients from Sanbo Brain Hospital and section 3 included 28 patients from the First Affiliated Hospital of University of Science and Technology
of China. At the bottom of the chart shows the details of the sample, including the detection method, the sample type, the presence or absence of a paired
blood sample, SF3B1R625H mutation detected, the Knosp classification, gender and group. Source data are provided as a Source Data file.
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splicing sites in SF3B1, in accordance with the known function of
SF3B1 in the recognition of branch-points and 3′ splice sites12.
Moreover, samples with SF3B1R625H showed a set of unique
aberrantly spliced junctions (Fig. 3a, Supplementary Fig. 6c). We
selected top 20 significant aberrant events (Supplementary
Table 5) and the involved gene targets in mutant and wild-type
tumors using the rMATS pipeline and further validated them
using RT-PCR, 15 events (14 genes) of which were verified
(Supplementary Fig. 7).
SF3B1 is an essential component of the U2 snRNP complex,
which binds pre-mRNA and carries sequence-specific RNA-
binding activity via the U2 auxiliary factor 2 (U2AF2) association
a
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with the pre-mRNA on the polypyrimidine track14,15. RBPmap16
scan of the U2AF2-binding motif (from CISBP-RNA17, id:
M077_0.6) on the 15 proven alternatively spliced events
demonstrated that all 14 genes had the binding motifs
recognized. ESRRG contained the most binding motifs (3088,
significantly more than others), and over half of the annotated
introns ended with the U2AF2-binding motif (Supplementary
Fig. 8a, b). Interrogation of the location distribution of U2AF2-
binding motif on ESRRG found that the U2 snRNP was
potentially related to the abnormal splicing of ESRRG (Supple-
mentary Fig. 8c). This suggested the impact of SF3B1R625H on
the splicing of ESRRG through association with the U2 snRNP.
ESRRG belongs to the ESRR family, which is closely associated
with the ER family and has common target genes, co-regulatory
factors, and promoters18, whereas ER is an established regulatory
factor of PRL synthesis and lactotroph proliferation19–21 and
binds to a single estrogen response element located within the
distal PRL enhancer.
Fig. 2 Downstream effects of the SF3B1 mutation. a PRL secretion in SF3B1 wild type and SF3B1 mutant primary human prolactinomas cells.
b Representative western blot for SF3B1 expression levels in primary human prolactinoma cells transfected with control or specific SF3B1 siRNA. β-actin
was used as internal control. c Suppression of the PRL secretion in primary human prolactinoma cells after the SF3B1 knockdown using SF3B1 siRNA. d PRL
secretion in primary human prolactinoma cells infected with Ad-null, Ad-SF3B1WT and Ad-SF3B1R625H are shown, respectively. e Focus formation was
assessed in GH3 cells infected with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H at the indicated MOI. f Results of CCK-8 cell proliferation assay showing in
GH3 cells infected with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H at the indicated MOI. g Annexin V/PI staining and flow cytometry showed the
percentages of apoptosis of the GH3 cells infected with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H. h Focus formations were assessed in MMQ cells
infected with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H at the indicated MOI. i Results of CCK-8 cell proliferation assay showing in MMQ cells infected
with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H at the indicated MOI. j Annexin V/PI staining and flow cytometry showed the percentages of apoptosis of
the MMQ cells infected with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H. c–i n= 9 per group. k Focus formations were assessed in stable GH3-control, GH3-
SF3B1WT, GH3-SF3B1R625H cells (n= 6 for GH3-control and n= 3 for two other cells). l Results of CCK-8 cell proliferation assay showing in stable GH3-
control, GH3-SF3B1WT, GH3-SF3B1R625H cells (n= 5 per group). m Annexin V/PI staining and flow cytometry showed the percentages of apoptosis of
stable GH3-control, GH3-SF3B1WT, GH3-SF3B1R625H cells. Data are represented as mean ± SD. The p value by two-tailed unpaired t test is indicated in a.
The p values by one-way ANOVA followed by Dunnett’s multiple comparisons test in c, d, k, l, m and followed by Tukey’s multiple comparisons post hoc
test in e, f, g, h, i, j are indicated. Source data are provided as a Source Data file.
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of ESRRG in SF3B1 mutant prolactinoma samples. The higher 278 bp band corresponds to the cryptic ESRRG transcript and the lower 257 bp band
corresponds to the canonical ESRRG transcript. d The graphs show expression levels of the cryptic ESRRG in normal pituitaries, SF3B1 mutant and SF3B1
wild-type prolactinoma samples (normal pituitary n= 2, mutant tumor n= 2, and wild-type tumor n= 4). e The qRT-PCR graphs show cryptic to canonical
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Tukey’s multiple comparisons post hoc test in d, e, g are indicated. Source data are provided as a Source Data file.
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RNA-seq showed significantly increased expression of ESRRG
in SF3B1R625H samples (Fig. 3b), which was not observed in wild-
type tumors and normal pituitaries. In the transcript-level analysis,
we found that the main contribution of the high expression of
ESRRG in mutant groups was from transcript NM_001243518.1
(hereafter, referred to as cryptic ESRRG transcript) (Supplemen-
tary Fig. 8d, e). It was consistent with the results of rMATS that
only the cryptic ESRRG transcript contained the aberrant splicing
event detected by rMATS. Alternative splicing of ESRRG was
significantly affected in the SF3B1 mutant samples, confirmed by
RT-PCR (Fig. 3c). The cryptic ESRRG transcript was only
observed in the SF3B1 mutant samples, but not in wild-type or
normal pituitaries, observed by qRT-PCR experiments (Fig. 3d, e).
To confirm the regulation of SF3B1R625H on ESRRG, we infected
the adenovirus carrying SF3B1R625H mutation in primary cultured
tumor cells, and the results showed that the cryptic ESRRG
transcript was only observed in the Ad-SF3B1R625H group (Fig. 3f).
The qRT-PCR results validated that SF3B1R625H could induce a
high cryptic to canonical isoform ratio in ESRRG in primary
human prolactinoma cells (Fig. 3g). The same results were also
observed in human MCF7 cells (human breast adenocarcinoma
cell) (Fig. 4a). Sanger sequence analysis showed that this was the
expected fragment with a 21 bp elongation of exon 5 (Fig. 4b, c).
We then investigated the alternative splicing using a minigene
splicing reporter system. The minigene construct contains a
fragment of the ESRRG gene spanning exons 5 and includes
353 bp of intron four sequences in this region (Fig. 4d). After
infection of adenovirus expressing SF3B1WT and SF3B1R625H,
respectively, this reporter was spliced to produce two major
products when co-transfected into MCF7 cells: a fully spliced RNA
containing exons 5 (Fig. 4e, left and middle lanes), and a larger
transcript that retained extra 21 bp (Fig. 4e, right lane). Sanger
sequencing analysis showed that these were the expected fragment
with extra 21 bp (Fig. 4f, g). The minigene results suggest that the
R625H mutation of SF3B1 does induce aberrant splicing of
ESRRG. The above results indicate that the ESRRG splicing pattern
is sensitive to the SF3B1 gene function.
SF3B1 interacts directly with ESRRG mRNA. To further
understand the mechanism of SF3B1-mediated ESRRG splicing,
we examined whether SF3B1 could bind directly to ESRRG. RNA
immunoprecipitation (RIP) demonstrated SF3B1 could bind
ESRRG mRNA in SF3B1 wild-type prolactinomas (Fig. 5a). In the
RIP complex of prolactinomas, we detected the cryptic ESRRG
only in SF3B1 mutant prolactinoma samples (Fig. 5b). This result
is consistent with the aforementioned cryptic ESRRG only
existing in SF3B1 mutant samples. This confirmed that the
SF3B1R625H would trigger the aberrant splicing in ESRRG.
Then, we analyzed the endogenous binding of SF3B1 to ESRRG
via a cross-linking immunoprecipitation and quantitative PCR
(CLIP-qPCR) assay22 in MCF7 cells, using 15 pairs of primers
with overlapping 100 bp amplicons, which allowed detection of
the protected ESRRG mRNA segments bound by SF3B1 and the
mapping of SF3B1-binding sites on ESRRG at 100-nt intervals
(Fig. 5c). Two major peaks were detected, suggesting that ESRRG
contains two SF3B1-binding sites, respectively, in the P12 and
P14 segments (Fig. 5c). The results further narrowed down the
major SF3B1-binding motif in the sequence around P12 and
P14 segments of ESRRG.
In order to compare the binding ability of wild-type and
mutant SF3B1 with ESRRG and confirm the binding sites of
mutant SF3B1 and cryptic ESRRG, we conducted CLIP experi-
ments in the wild-type and SF3B1 mutant prolactinomas tissue
samples, respectively. As shown in Fig. 5d, consistent with the
results of MCF cells, the P12 and P14 segments of ESRRG showed
the highest binding ability to SF3B1 in wild-type prolactinomas.
Compared with the canonical ESRRG, the cryptic ESRRG had an
extra 21 bp of the exon 5, so we designed primers for this unique
21 bp in cryptic ESRRG (P8, only exists in cryptic ESRRG
sequence) and corresponding fragment (P18, only exists in
canonical ESRRG sequence) in canonical ESRRG. The results
(Fig. 5e) showed that in the SF3B1 mutant prolactinomas
samples, P8 segment instead of P12/P14 had the highest
enrichment value, which reached 1016, far higher than the
second 95 (P15). The enrichment value of P8 in cryptic ESRRG is
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very high, whereas the enrichment of corresponding P18 in
canonical ESRRG is not obvious. These results suggest that the
mutant SF3B1 has a strong binding ability with the extra 21 bp of
cryptic ESRRG.
Cryptic ESRRG binds Pit-1 with greater affinity. Pit-1 is crucial
for the pituitary-specific expression of the PRL gene23–25. To
determine whether there is a direct interaction between Pit-1 and
ESRRG, we immunoprecipitated Pit-1/ESRRG from human PA
lysates and probed with ESRRG/Pit-1 antibody, respectively. The
results indicate a physical interaction between Pit-1 and ESRRG
in human PA (Supplementary Fig. 9). Then we examined Pit-1
protein binding in relation to ESRRG alternative splicing status.
Pit-1 protein fused to glutathione S-transferase (GST) pull-down
HIS-tagged cryptic ESRRG, whereas it bound weakly to canonical
ESRRG (Fig. 5f). We next co-expressed Flag-tagged Pit-1 HA-
tagged ESRRG in human embryonic kidney cells 293 (HEK293)
cells and immunoprecipitated them with anti-Flag antibody. As
determined by co-immunoprecipitation, cryptic ESRRG binds
strongly to Pit-1, whereas canonical ESRRG retained weak
binding (Fig. 5g). HEK293 cells were measured by luciferase
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reporter assay with transiently co-expressed Pit-1, PRL promoter,
cryptic, and canonical ESRRG clones. The cryptic ESRRG
demonstrated stronger PRL transcriptional activation than the
canonical ESRRG (Fig. 5h). Thus, these results demonstrate that
cryptic ESRRG has a stronger affinity to bind to the Pit-1,
potentially resulting in increased activation of PRL transcription.
The effects of aberrant splicing on ESRRG. The reduced
expression of ESRRG by siRNA (70–80% reduced) in transduced
primary cultured prolactinoma cells resulted in a significant
reduction of PRL secretion (Fig. 6b) in culture media, confirmed
by qRT-PCR and western blot (Fig. 6a, Supplementary Fig. 10).
Further, we infected the primary culture prolactinoma cells with
adenovirus with canonical and cryptic ESRRG, respectively.
Cryptic ESRRG resulted in a significant augment of PRL secretion
(Supplementary Fig. 11). These results indicate that the cryptic
ESRRG, resulting from SF3B1R625H contributes to an excess of
PRL activation in prolactinomas, beyond physiologic with the
canonical ESRRG in the pituitary.
We then investigated the effect of ESRRG on the prolactinoma
cell proliferation and growth. After infection of adenovirus
expressing canonical ESRRG and cryptic ESRRG, respectively,
CCK-8 assay was performed to detect the effect of ESRRG on the
proliferation. These results showed that ESRRG increased the
growth of GH3 and MMQ cells compared with control (Fig. 6c,
d). Both canonical ESRRG and cryptic ESRRG overexpression by
adenovirus can improve the focus formation of GH3 and MMQ
cells (Fig. 6e, f and Supplementary Fig. 12). PI staining and flow
cytometry results revealed that the percentages of early and late
apoptosis of GH3 and MMQ cells were decreased by canonical
ESRRG and cryptic ESRRG compared with control (Fig. 6g, h,
Supplementary Fig. 13). Considered together, these data indicate
that ESRRG, especially cryptic ESRRG enhances proliferation and
suppresses apoptosis of GH3 and MMQ cells.
Clinical relevance of SF3B1 mutation. Clinical characteristics of
the 227 patients with prolactinomas were analyzed, 45 of whom
contained SF3B1R625H mutation. Clinical features including age,
tumor size, and tumor invasion showed no significant difference
between the two groups. However, gender analysis revealed that
there was a significant male preference in the mutant population
(p= 0.02, Pearson’s χ2 test; Fig. 7a, Table 1). The frequency of
SF3B1R625H mutation in male patients was 24.34% compared with
10.67% in female patients. Patients with mutant SF3B1 showed
higher levels of PRL (plasma PRL/tumor size), as compared with
the wild-type group. This suggested that the SF3B1 mutant pro-
lactinomas have higher PRL production than the wild-type group
(p= 0.02, Mann–Whitney U test, Fig. 7b, Table 1). Most
importantly, according to the maximum duration of 10-year
follow-up data, we observed that the mutated SF3B1 group was
significantly associated with poor progression-free survival
(Fig. 7c). In two mutant cases of our discovery cohort, the pro-
lactinomas displayed unusual malignancy. These two patients
even suffered from additional surgeries within 2 years because of
rapid residual tumor regrowth. Although limited by case number,
this evidence supports that SF3B1R625H may contribute to an
enhanced malignancy of prolactinomas.
Discussion
The driving genetic events that contribute to prolactinoma
tumorigenesis remain unknown. We performed genomic analysis
of 21 prolactinomas by WGS and recurrent SF3B1R625H mutation
was found in two tumors. We performed digital PCR in a vali-
dation set of 227 prolactinomas and identified 45 tumors (19.8%)
with the hotspot SF3B1R625H mutation. The mutation was not
detected in other types of PAs besides two mixed PAs with
positive PRL immunohistochemical staining. Therefore, the
SF3B1R625H mutation appears to be a unique genetic signature of
PRL-secreting adenomas.
SF3B1 has an important oncogenic role in the pathogenesis and
development of many tumors. Those reported SF3B1 mutations
are nearly all located in the C-terminal HEAT domains (residues
622–781). For instance, E662D, K666Q, K700E, and G724D were
common in CLL11. In uveal melanomas, although R625 was the
predominant mutation, several forms including R625C, R625G,
R625H, and R625L could be detected8.
Here, we demonstrated that our subset of prolactinomas har-
bored SF3B1R625H mutation, which has been predicted to be more
deleterious and probably oncogenic6. We then confirmed that this
mutation resulted in a gain-of-function of ESRRG through
alternative splicing. ESRRG belongs to the ESRR family whose
biological functions are involved in estrogen-signaling pathways.
We found that aberrant ESRRG is transcriptionally active and
induces abnormal PRL transcription, which suggests that the high
levels of PRL in SF3B1 mutant prolactinomas are likely to be
caused by this pathway. Data evaluation captured a gender pre-
ference in the prolactinoma mutant subset with 24.34% of the
total population of males versus 10.67% of females. This is dif-
ferent from the historically observed female gender dominance of
prolactinomas26,27. The ESRRG mediated mechanism of PRL
secretion showed ER independence, supporting the observed
gender distribution.
In the present study, we established the role of the recurrent
SF3B1R625H mutation in this subset of prolactinomas. The
SF3B1R625H mutation promotes PRL hypersecretion through
aberrant ESRRG splicing via a stronger affinity for Pit-1, resulting
in greater transcriptional activation of PRL (Fig. 7d). The muta-
tion leads to enhanced cell proliferation and decreased apoptosis
of prolactinoma cells. The study demonstrated that SF3B1
mutation was significantly associated with poor prognosis in
Fig. 5 The effects of aberrant splicing on ESRRG. a ESRRG mRNA levels in immunoprecipitates were determined through qRT-PCR analysis (n= 3 per
group). ESRRG mRNA expression levels were presented as fold enrichment ratios compared with IgG. b Cryptic ESRRG mRNA levels in immunoprecipitates
of wild-type and mutant primary human prolactinoma cells were determined by qRT-PCR (n= 3 per group). Expression levels of ESRRG mRNA were
presented as fold enrichment ratios compared with IgG. c–e CLIP of SF3B1-bound ESRRG mRNA in MCF7 cells c, SF3B1WT prolactinomas d, or SF3B1R625H
prolactinomas e (n= 3 per group). qPCR was used to identify the region in ESRRG bound by SF3B1 protein. The amount of immunoprecipitated RNAs in
each sample is represented as a signal relative to the negative (IgG) sample. Schematic representation of human ESRRG segments amplified by primer
pairs for CLIP-qPCR. f GST-Pit-1 fusion protein immobilized on glutathione beads and incubated with HIS-tagged cryptic or canonical ESRRG proteins.
Bound ESRRG proteins were detected by anti-HIS immunoblotting. g Immunoblotting with the indicated antibodies of FLAG immunoprecipitated from
lysates of HEK293 cells co-transfected with FLAG-tagged Pit-1, HA-tagged cryptic, or canonical ESRRG. h Relative luciferase activity of PRL promoter in
HEK293 cells transfected with pCDNA3.1-Pit-1 (Pit-1), pGL3-basic-PRL promoter (PRL-p), or pCDH-ESRRG-canonical/cryptic and their corresponding
empty vectors including pCDNA3.1, pGL3-basic, and pCDH. pRL-TK was used as a control (n= 4 per group). Results are expressed as mean ± SD. The
p values by one-way ANOVA followed by Dunnett’s multiple comparisons test in a and followed by Bonferroni’s multiple comparisons test in h are
indicated. The p value by two-tailed unpaired t test is indicated in b. Source data are provided as a Source Data file.
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patients with prolactinomas. Although continued postoperative
treatment of prolactinomas with dopamine agonists for control of
PRL levels owing to possible residual or recurrent tumors is a
standard measure, which may make PFS difficult to assess, we
believe that this mutation has clinical relevance in defining
prognostic subgroups and implications for developing precision
therapeutic targeting, as evidenced by our significant correlation
herein.
In conclusion, we identified SF3B1R625H as a disease-causative
mutation in a subset of prolactinomas and elucidated a cellular
mechanism in which alternative splicing of ESRRG pre-mRNAs is
constitutively activated and results in estrogen-independent
increased PRL section in these tumors. In subsequent studies,
we might control excessive PRL secretion in prolactinomas by
targeting different alternative splicing form of ESRRG.
Methods
Study patients. We retrospectively reviewed 381 PAs including prolactinomas
n= 227, other PAs n= 154 (18 thyrotroph, 33 somatotroph, 30 gonadotroph, 24
corticotroph, 15 null cell, 16 plurihormonal, and 18 mammosomatotroph/mixed
somatotroph and prolactinomas) from patients who underwent surgery for PA at
Beijing Tiantan Hospital, Sanbo Brain Hospital Capital Medical University and The
First Affiliated Hospital of University of Science and Technology of China. All 227
prolactinoma patients had plasma PRL levels of > 90 ng ml−1 and tumor with
positive immunostaining for PRL (Supplementary Table 6). All diagnoses of
prolactinomas were confirmed by a multidisciplinary group consisting of neuro-
surgeons, neuroradiologists, and neuropathologists (Supplementary Table 7) and
normal human anterior pituitaries were obtained from a donation program and the
donors died of non-endocrine diseases.
Study design. The main study group comprised patients from Beijing Tiantan
Hospital affiliated to Capital Medical University. Tissue samples of prolactinomas
and peripheral blood samples were obtained from these patients, flash-frozen, and
stored at Beijing Neurosurgical Institute, Beijing, China. WGS was performed to
detect somatic mutations on the initial patient set (n= 21). The results of DNA
sequencing were confirmed with microfluidic-chamber-based digital PCR analysis
or Sanger sequencing. All procedures performed with the use of samples obtained
from patients were approved by the Ethics Committee of Beijing Tiantan Hospital.
All the patients signed informed consent.
The remaining 360 patients were screened for mutation validation. The
validation group comprised PA patients from Beijing Tiantan Hospital affiliated to
Capital Medical University, Sanbo Brain Hospital (validation set 1) and The First
Affiliated Hospital of University of Science and Technology of China (validation
set 2). Microfluidic-chamber-based digital PCR analysis was performed to detect
SF3B1 mutations in all sets of patients. DNA samples were obtained from formalin-
fixed, paraffin-embedded tissues of PAs from these patients. The PA patient groups
can be seen in Supplementary Table 1.
RNA sequencing. RNA-seq was performed in two SF3B1 mutant tumors, 13
SF3B1 wild-type tumors and 10 normal pituitary glands. A total amount of 3 μg
RNA per sample was used as input material for RNA sample preparations. First,
ribosomal RNA was removed by Epicentre Ribo-zero rRNA Removal Kit
(RZH1046, Epicentre). Subsequently, sequencing libraries were generated using the
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Fig. 6 Downstream effects on aberrant splicing on ESRRG. a The qRT-PCR results display ESRRG mRNA expression levels in primary human prolactinoma
cells transfected with control or specific ESRRG siRNA. GAPDH was used as an internal control (n= 3 per group). b Suppression of PRL secretion in
primary human prolactinomas cells after ESRRG knockdown using ESRRG siRNA (n= 9 per group). c Results of CCK-8 cell proliferation assay in GH3 cells
infected with Ad-null, Ad-canonical ESRRG, and Ad-cryptic ESRRG (n= 5 per group). d Results of CCK-8 cell proliferation assay in MMQ cells infected with
Ad-null, Ad-canonical ESRRG, and Ad-cryptic ESRRG (n= 5 per group). e Focus formation was assessed in GH3 cells infected with Ad-null, Ad-canonical
ESRRG and Ad-cryptic ESRRG (n= 9 per group). f Focus formations were assessed in MMQ cells infected with Ad-null, Ad-canonical ESRRG, and Ad-
cryptic ESRRG (n= 9 per group). g Annexin V/PI staining and flow cytometry showed the percentages of apoptosis of the GH3 cells infected with Ad-null,
Ad-canonical ESRRG, and Ad-cryptic ESRRG (n= 9 per group). h Annexin V/PI staining and flow cytometry showed the percentages of apoptosis of the
MMQ cells infected with Ad-null, Ad-canonical ESRRG, and Ad-cryptic ESRRG (n= 9 per group). Results are expressed as mean ± SD. The p values by one-
way ANOVA followed by Dunnett’s multiple comparisons test in a, b and followed by Tukey’s multiple comparisons post hoc test in c–h are indicated.
Source data are provided as a Source Data file.
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rRNA-depleted RNA by NEBNext Ultra Directional RNA Library Prep Kit for
Illumina (E7420L, NEB) following the manufacturer’s protocol. First strand cDNA
was synthesized using random hexamer primer. Second-strand cDNA synthesis
and making, which incorporates dUTP into the second strand, converts the cDNA.
Double-stranded DNA was repaired via exonuclease/polymerase activities and then
added adenylation to the 3′ end. After adapter ligation and library amplification,
the library fragments were purified with AMPure XP system (Beckman Coulter,
Beverly, USA) in order to select fragments of preferentially 150–200 bp in length.
The strand marked with dUTP is not amplified, allowing strand-specific sequen-
cing. At last, products were purified (AMPure XP system) and library quality was
assessed on the Agilent Bioanalyzer 2100 system. After cluster generation, the
libraries were sequenced on an Illumina Hiseq X platform and 150 bp paired-end
reads were generated.
Alternative splicing analysis. Alternative 3′ and 5′ splice sites, skipped exons,
mutually exclusive exons, and retained introns were quantified using rMATS28
(http://rnaseq-mats.sourceforge.net/index.html). The default parameters were used
for the comparison of two groups, which carrying p. R625H hotspot mutation on
SF3B1 (SF3B1R625H) and wild-type samples (SF3B1WT). The alternative spliced
events with a false discovery rate < 0.05 and inclusion level difference values > 0.3
or <−0.3 were selected for endpoint reverse transcriptase-PCR (RT-PCR)
validation.
The ref. 29 analyzed the cryptic splicing event by setting a cutoff value for the
results of rMATS. So, we use a similar criterion to define the cryptic transcripts: we
collected data sets from the rMATS output on the basis of FDR < 0.05. Then we
selected top 20 significant aberrant events (IncLevelDifference > 0.3 or
IncLevelDifference <−0.3) and the involved gene targets in mutant and wild-type
tumors using the rMATS pipeline and further validated them using RT-PCR. We
define it as cryptic transcripts that dominant transcriptional isoform in mutants,
similarly as canonical transcripts in wild type.
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Fig. 7 Clinical relevance of the SF3B1 mutation. a The gender distribution is shown within different groups (mutant group n= 45 and wild group n= 182).
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in prolactinomas. The p values by chi-square test in a and by two-tailed Mann–Whitney test in b are indicated. The p value by log-rank (Mantel–Cox) test is
indicated in c. Source data are provided as a Source Data file.
Table 1 Clinical characteristics of prolactinoma patients.
Characteristic Wild type Mutant P value
Age at diagnosis (year)
Median 38.00 39.00 0.45#
Interquartile range 21.75 16.00
Sex (case)
Male 115 37 0.02*
Female 67 8
PRL (ng ml−1)/tumor size (cm)‡
Median 288.12 385.58 0.02#
Interquartile range 398.19 552.11
Tumor invasion (case)
Non-invasion 84 27 0.10*
Invasion 75 13
Tumor size (cm)‡
Median 2.80 2.60 0.74#
Interquartile range 1.60 2.03
Age and sex data were available for 182 patients with no mutation and 45 patients with the
mutation. PRL/tumor size, tumor invasion, and tumor size data were available for 159 patients
with no mutation and 40 patients with mutation. In total, 28 cases from the First Affiliated
Hospital of University of Science and Technology of China were excluded from statistical
analysis because of different PRL dilution measurement protocol.
#Values were compared by two-tailed Mann–Whitney U test.
*Values were compared by Pearson’s χ2 test.
‡Tumor size: maximal tumor diameter.
Source data are provided as a Source Data file.
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Unsupervised hierarchical clustering of the samples. Unsupervised clustering of
SF3B1R625H and SF3B1WT tumors use the alternative spliced events with p value <
0.05. Taken the batch effect into consideration, we proceeded with unsupervised
hierarchical clustering selecting the top 5000 most viable A3SS alternative splicing
events to separate and cluster samples.
Binding motif analysis of U2AF2. As mentioned in the main content, SF3B1 is an
essential component of the U2 snRNP complex, which binds pre-mRNA via the
U2AF2. Therefore, we extracted the sequences of the 14 proved alternatively
spliced genes from the reference genome (hg19) and uploaded them to RBPmap
web server (http://rbpmap.technion.ac.il/) for detecting the existence of the
U2AF2-binding motif (provided by CISBP-RNA database, id: M077_0.6) with
default parameters. The results in Supplementary Fig. 8a showed that ESRRG
contains a significant number of the U2AF2-binding motifs, indicating a great
potential to be aberrantly spliced owing to the mutation in SF3B1. Also, the role
and function of ESRRG in PRL synthesis and prolactinomas proliferation (men-
tioned in the main content) attracted our attention to performing detailed analysis
on ESRRG.
When splicing, the U2 snRNP complex will interact with the polypyrimidine
track with the length of 15~20 bp and located about 5~40 bp before the 3′ end
of the intron to be spliced. Under this fact, we extracted the sequences of the last
100 bp at the 3′ end of introns in all annotated transcripts of ESRRG (from RefSeq
reference transcriptome, version GRCh37.p13) and further verified the existence of
the U2AF2-binding motif on RBPmap web server. The results were shown in
Supplementary Fig. 8b and c.
Differential expression analysis of ESRRG on gene- and transcript-level.
Owing to the splicing of ESRRG is potentially related to the mutation in SF3B1, we
analyzed the differential expression of ESRRG in two comparison groups: mutant
tumor vs normal pituitary and wild-type tumor vs normal pituitary. This setting
regarded the normal pituitary as the background and was designed for detecting
the variation of ESRRG expression in tumors with/without the SF3B1 mutation.
The quantification of transcript-level expression was done by Salmon (https://
combine-lab.github.io/salmon/), which is the state-of-the-art tool, with the refer-
ence transcriptome from RefSeq (GRCh37.p13), and the differential expression
analysis was finished by DESeq2 (https://bioconductor.org/packages/release/bioc/
html/DESeq2.html). Both tools were executed by default parameters. The
transcript-level results were shown in Supplementary Fig. 8d and e, which led us to
recognize the cryptic ESRRG transcript NM_001243518.1. The gene–level analysis
can be easily converted by aggregating the transcript-level results, shown as Fig. 3b.
Digital droplet PCR (ddPCR). Detection of rare variants in SF3B1 was performed
on the EP1 Digital Array (Fluidigm) Digital PCR system. The SF3B1 mutation
analysis is based on allele-specific PCR. We designed external primers for com-
plementary probe regions and TaqMan MGB probes (TsingKe Biological Tech-
nology) to detect the mutations in SF3B1 c.1874G > A. One probe targets the
mutant variant (tagged with Applied Biosystems’ proprietary 5-hexachloro-
fluorescein (HEX) fluorophore), and the other targets a wild-type variant (tagged
with the 6-carboxyfluorescein (FAM) fluorophore). The TaqMan MGB probes and
primers used for ddPCR were listed in Supplementary Table 11.
Two different arrays were used. To test the effects of different PCR components,
1) the 12.765 array (BMK-M10-12.765, Fluidigm) was used with 8 μL reaction
mixtures comprising 0.8 μL DNA sample, 0.4 μL 20× GE Sample Loading Reagent
(PN 85000746, Fluidigm), 2.8 μL 10 μM gene-specific assays (genotyping primer
and TaqMan probes specific for mutated and wild-type SF3B1) and 4 μL TaqMan
Gene Expression Master Mix (PN 4369016, Life Technologies); 2) the 48.770 array
(dPCR 37k IFCs, 100-6151, Fluidigm) was used with 4 μL reaction mixtures
comprising 0.88 μL DNA sample, 0.4 μL 20×GE Sample Loading Reagent, 0.72 μL
20 μM gene-specific assays and 2 μL 2× TaqMan Gene Expression Master Mix. The
loaded arrays were then transferred to the EP1 Cycler. Thermocycling was
performed as follows: 120 s at 50 °C, a hot start at 95 °C for 10 min, and 40 cycles of
15 s of denaturation at 95 °C, and 1 min of annealing and extension at 60 °C.
EP1 Data Collection and Analysis Software was used to process the data,
analyze PCR amplification, and count the numbers of HEX-positive chambers and
FAM-positive chambers in each panel. We used 6-carboxy-X-rhodamine signals as
an internal positive PCR control. Positive and negative controls were used to assess
platform function, amplification protocol and to establish the Cq range and the
quantification threshold. A total of 450 bp synthetic DNA fragments for SF3B1
c.1874G > A were used as positive controls (TsingKe Biological Technology). DNA
from a healthy individual was used as a negative control.
To determine the specificity of the assay, we performed ddPCR using water and
healthy control DNA as a negative control. In control experiments, where no
template was added, generally, no positive chambers were detected. Rarely, one to
two chambers representing mutant amplimer were detected in healthy control
DNA. We set a minimum cutoff frequency of 0.5% (one mutant per 200 total
alleles) to call a DNA sample positive for a SF3B1 mutation by ddPCR.
Representative ddPCR outputs are shown in Supplementary Table 3. For all
samples, the c.1874G > A ddPCRs were performed at least three times.
Cell culture and adenoviral constructs. MCF7 cells and rat PA cells (GH3 and
MMQ) were originally obtained from the American Type Culture Collection
(ATCC) and cultured at 37 °C in 35 mm dishes in a humidified atmosphere of 95%
air and 5% CO2. The culture medium of GH3 and MMQ were Ham’s F12K
medium with 2.5% fetal bovine serum (FBS) and 15% horse bovine serum. The
culture medium of MCF7 was Eagle’s Minimum Essential Medium with 10% FBS.
Cultures were fed every other day. The cell lines were also genotyped to rule out
cross-contamination and their morphology was regularly examined.
Prolactin levels were measured using an ELISA kit (K4688, BioVision)
according to the manufacture’s protocol. We used HEK293 cells as a non-pituitary
control. The SF3B1R625H mutant was generated from the human wild-type SF3B1
construct (I1439, obtained from GeneCopoeia), by point mutation using a site-
directed mutagenesis kit (210518, QuikChange II, Stratagene). DNA fragments
corresponding to full-length (canonical) or cryptic (contains additional 21 bp)
ESRRG were amplified from a human cDNA library by PCR and inserted into
pDC316-mCMV-ZsGreen expression Vector (Sigma-Aldrich) using the NheI and
NotI restriction sites. Adenoviruses expressing each of these constructs were
constructed by BAC Biological Technology.
CCK-8 assay cell growth viability. Cells after treated or untreated were seeded at
a concentration of 4 × 103 per well in the 96-well plate. Each group was detected
with Cell Counting Kit-8 (Beyotime, C0039), following the manufacturer’s
instructions. In brief, 10 µl CCK-8 were added into each well, and cells were
incubated for an additional 4 h. The absorbance at 450 nm was measured using a
microplate reader.
Apoptosis analysis. Cells were analyzed for apoptosis by an Annexin V-FITC/PI
double-staining method described by kit manufacturer (Beyotime, C1062M). The
cells 48 h after treatment were collected and subjected to the analysis. About 5 × 105
cells each group were collected by centrifugation and resuspended 500 µl of binding
buffer. 5 µl of Annexin V-FITC and 5 µl of PI were added into each tube, then
incubated at room temperature for 15 min in the dark. Stained cells were analyzed
by flow cytometry in FITC and PE channels.
Colony formation assay. Single-cell suspensions of 1 × 103 cells were plated in
2 mL of Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS. During
3 weeks of cell culture, the medium was changed every 3 days. Then the colonies
were fixed in 4% paraformaldehyde, and stained with 0.04% crystal violet in PBS
for 15 min at room temperature. After extensive washing and air drying, the colony
numbers were measured by ImageJ.
GST pull-down. In all, 500 μg HIS-cryptic ESRRG protein, 200 μl immobilized
GST-tag Purification Resin and 500 μg GST-Pit-1 protein were added to 1000 μl
pull-down buffer (50 mM Tris, 150 mM NaCl, 0.1% Triton X-100, 10 mM EDTA,
1 mM PMSF, 1% protease inhibitor cocktail (pH 8.0)), then incubated at 4 °C for
16 h. Similarly, HIS-canonical ESRRG protein was incubated with immobilized
GST-Pit-1 protein. As a negative control, HIS-cryptic ESRRG protein and HIS-
canonical ESRRG protein was incubated with GST protein. Beads were washed four
times with the pull-down buffer. Retained proteins were released by adding 2×
loading buffer and boiled for 5 min at 95 °C, then resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected by the GST
monoclonal antibody (CUSABIO, CSB-MA000304, 1:200) and His-Tag Mono-
clonal antibody (CUSABIO, CSB-MA000159, 1:200).
Immunoprecipitation and immunoblotting. FLAG-Pit-1 and HA-cryptic ESRRG
co-transfected cell extract, 50 μl immobilized protein G Agarose, and 10 μg FLAG
antibody (ABclonal, AE005, 1:100) were added to 1000 μl of CoIP buffer (50 mM
Tris, 150 mM NaCl, 0.1% Triton X-100, 1 mM PMSF, 1% protease inhibitor cock-
tail), then incubated at 4 °C for 16 h. Similarly, FLAG-Pit-1 and HA-canonical
ESRRG co-transfected cell extract was incubated with FLAG antibody. Human
prolactinomas lysates were immunoprecipitated with Pit-1 (Santa Cruz Bio-
technology, sc-25258, 1:500) or ESRRG (Abcam, ab16366, 1:100) antibody. As a
negative control, cell extract was incubated with mouse IgG. Beads were washed
four times with the CoIP buffer. Retained proteins were released by adding 2×
loading buffer and boiled for 5 min at 95 °C, then resolved by SDS-PAGE and
detected by the Mouse anti-FLAG mAb, anti-HA (Abcam, ab9110, 1:500), anti-
ESRRG and anti-Pit-1. GAPDH (Abcam, ab8245, 1:5000) was used as an internal
control in western blot.
The simple western immunoblots were performed on a Wes (ProteinSimple)
using the Jes/Wes Separation Master Kit (12–230 kDa) according to the
manufacturer’s standard instruction, using the following antibodies: anti-ESRRG
(Abcam, ab49129, 1:400), anti-SF3B1 (Novus, NB100-55255, 1:400) and anti-β-
actin (Abcam, ab8227, 1:1000).
RNA immunoprecipitation (RIP). RNA immunoprecipitation was used to
investigate whether ESRRG could bind with the potential binding protein SF3B1.
We used the EZ-Magna RIP kit (17-701, Millipore) following the manufacturer’s
protocol. Cells were lysed in complete RIP lysis buffer, and the extract was
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incubated with magnetic beads conjugated with antibodies that recognized SF3B1
antibody (sc-514655, Santa Cruz Biotechnology, 1:100) or control IgG (Millipore)
for 6 h at 4 °C. Then, the beads were washed and incubated with Proteinase K to
remove proteins. Finally, purified RNA was subjected to qRT-PCR analysis to
demonstrate the presence of ESRRG uses specific primers. Primer pairs for RIP
were listed in Supplementary Table 9.
UV CLIP and qPCR. The CLIP assay was adapted from the previous publications22.
Specifially, MCF cells were washed in ice-cold PBS and PBS was removed com-
pletely. Plates were placed in a UV crosslinker and irradiated with 150 mJ cm−2 of
UVA (365 nm) before being lysed. After lysis, cell lysates were incubated with
RNase T1 (ThermoFisher Scientific, EN0541) at 1 U μl−1 at 22 °C for 6 min to
digest RNAs that were not protected from bound proteins, then subjected to
immunoprecipitation with an anti-SF3B1 (sc-514655, Santa Cruz Biotechnology)
or IgG antibody following standard RIP protocol22. The immunoprecipitated RNA
was isolated using the PureLink RNA Mini Kit (ThermoFisher Scientific, 12183018
A) with DNase treatment. After reverse transcription (Takara, 638313), the
resultant cDNA was subjected to qRT-PCR assay. The primers used for qRT-PCR
were designed to cover the full-length human ESRRG sequence and listed in the
Supplementary Table 8. Data are normalized to IgG (SF3B1 IP/IgG IP).
Culture of primary human prolactinoma cells. Human prolactinomas were
obtained at the time of surgery and transferred in fresh L15 medium enriched with
10% FBS. The PAs tissues were cut into small pieces and then were digested with
collagenase (1 mgml−1; 17101015, Thermo Fisher) for 30 min at 37 °C. After
terminating the enzymatic treatment by addition of FBS, the mixture was filtered
with cell strainer to remove undigested tissues and centrifuged at 600 × g for 5 min.
The cell pellet was resuspended in Neurobasal growth medium supplemented with
2% B27 (A3582801, Thermo Fisher) and plated on 35 mm dishes. Tumor cells were
infected with adenovirus at MOI of 30 or 100 for 48 h. Tumor cells were digested
and centrifuged for 5 minutes and suspended in the medium. Live cells were cal-
culated and re-plated in 24-well plates. The supernatant was collected for analysis
for prolactin secretion after 24-hour culture. Prolactin levels were measured using
an enzyme-linked immunosorbent assay (ELISA) (CSB-E06883h, Cusabio)
according to the manufacture’s protocol.
Transfection and RNA interference. siRNA transfections were performed using
Lipofectamine 2000 (11668019, Thermo Fisher), according to the manufacturer’s
protocol. siRNA synthesis was performed by Shanghai GenePharma and the siRNA
sequences for human SF3B1 are shown in Supplementary Table 9.
QRT-PCR. Total RNA was extracted using RNeasy Mini Kit (74104, Qiagen) and
then reversed transcribed using High Capacity cDNA Reverse Transcription Kit
(4368814, Thermo Fisher) according to the manufacturer’s instructions. Subse-
quently, we performed qRT-PCR using Power SYBR Green PCR Master Mix
(4367659, Thermo Fisher) in a total reaction volume of 10 μL. GAPDH was used as
a reference gene. The levels of mRNAs were performed on an ABI 7500 System
(Applied Biosystems). Primer pairs for qRT-PCR are shown in Supplementary
Table 9. Amplification was performed as follows: 95 °C for 10 min and 40 cycles at
95 °C for 15 sec, 60 °C for 60 sec. For the quantitative analysis, relative expression
levels were calculated based on CT values (corrected for GAPDH expression)
according to the equation: 2−ΔCT [ΔCT= CT (gene of interest) – CT (GAPDH)].
All qRT-PCR analyses were performed in triplicate.
Total RNA was extracted using RNeasy Mini Kit (74104, Qiagen), and reverse
transcription was performed using High Capacity cDNA Reverse Transcription Kit
(4368814, Thermo Fisher) according to the manufacturer’s protocol. Subsequently,
we performed PCR using I-5 High-Fidelity Master Mix (I5HM - 200, MCLAB).
The thermocycling protocol was listed as follows: initial denaturation at 98 °C for 2
min, followed by 32 repeats of the three-step cycling program consisting of 10 sec
at 98 °C (denaturation), 10 sec at 59 °C (primer annealing) and 10 sec at 72 °C
(elongation), followed by a final extension step for 5 min at 72 °C. Primers were
designed to obtain an amplification product that spans the Cufflinks-predicted
alternative splicing junctions. PCR reactions were carried out using primers/
conditions described in Supplementary Table 10, and PCR products were run on
1–3% agarose gel and visualized using a UV transilluminator.
Luciferase reporter assays. A reporter gene containing an upstream fragment of
2 kilobases of the 5′ promoter region in the human PRL gene linked to pGL3-basic
reporter vector. ESRRG-cryptic (NM_001243518.1), ESRRG-canonical
(NM_001243519.1) cDNA were, respectively, cloned into pCDH vector. Human
Pit-1 cDNA (NM_000306.1) was respectively cloned into pCDNA3.1 vector. All
constructs were verified by Sanger sequencing (TsingKe Biological Technology).
HEK293 cells were cultured at 37 °C in a humidified atmosphere of 95% air and 5%
CO2. The culture medium was DMEM with 10% FBS. Cultures were fed every
other day. The cell lines were also genotyped to rule out cross-contamination and
their morphology was regularly examined. HEK293 cells were transfected in 24-
well plates containing 2 μL of Lipofectamine 2000, 1 μg of pCDH-ESRRG-cryptic/
pCDH-ESRRG-canonical and/or pCDNA3.1/ pCDNA3.1-Pit-1, 1 μg of pGL3-basic
or pGL3-basic-pRL-p, and 100 ng of pRL-TK-Renilla (as transfection control) for
48 h. The cells were lysed in buffer (100 μL lysis buffer, Promega Corporation) and
luciferase activity was then measured in a Mithras LB 940 apparatus (Berthold
Technologies). The different vectors transfection groups are shown in Supple-
mentary Table 12.
Statistical analysis. The statistical analysis was performed using SPSS version 22.0
(SPSS Inc.) and graphs were prepared with Prism 7.0 (GraphPad) software. T test
or Mann–Whitney U test were performed for comparison of continuous variables
between two groups. Comparison of three or more groups was performed with
one-way analysis of variance followed by Tukey’s multiple comparisons post hoc
test, Dunnett’s multiple comparisons test or Bonferroni multiple comparisons test.
Pearson’s χ2 test was performed for comparison of categorical variables between
two groups. All the experiments were performed in triplicates. P < 0.05 was con-
sidered to indicate statistical significance.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw sequence data reported in this paper have been deposited in the Genome
Sequence Archive in BIG Data Center, Beijing Institute of Genomics (BIG), Chinese
Academy of Sciences, under accession numbers HRA000041, HRA000041 that can be
accessed at https://bigd.big.ac.cn/gsa-human/browse/HRA000041. The deposited and
publicly available data are compliant with the regulations of the Ministry of Science and
Technology of the People’s Republic of China. The raw sequencing data and somatic and
germ-line mutation calls contain information unique to an individual, require controlled
access, all data are available from the corresponding author upon reasonable request. The
source data underlying Table 1, Figs. 1, 2, 3a, b, d, e, g, 5a–e, h, 6, 7a, b and
Supplementary Figs 3a, 6a–c, 8d, and 11 are provided as a Source Data file.
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